SEC Form 4 · accession 0001209191-17-065064
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Engelhart
Officer — Chief Financial Officer
Period of report
Dec 7, 2017
Accepted (ET)
Dec 11, 2017 · 5:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $20.79 | Dec 7, 2017 | A | 78,264 | A | — | Dec 6, 2027 | Common Shares | 78,264 | 78,264 | D |
Explanation of responses
- F1The shares underlying this option vest in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the issuer at each vesting date.